Autologous Cytokine-induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission

Overall Survival

Overall Survival

CONTACT US

Summary

This study aimed to evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR). As a result, Autologous CIK cell immunotherapy has emerged as a safe and efficacious option to improve the prognosis of patients with high-risk DLBCL after the first CR.

Patients characteristics

The study population included 40 patients with high-risk diffuse large B cell lymphoma and divided into two groups, 20 patients receiving CIK treatment (9 females; mean age=58±14 years) and 20 subjects as the control group (9 females; mean age = 57±14 years). Characteristics of the patients were relatively well balanced.

Methodology

CIK cell preparations
Peripheral venous blood (60 mL) from patients was collected to extract PBMCs. The cells were incubated in a cell incubator at 37°C with 5% CO2. A total of 1000 U of rhIFN-γ was added to 1 mL of cell suspension (cell density was approximately 1–2×106/mL) on the first day.
After 24 h, rhIL-2 (1000 U/mL) and anti-CD3 mAb (10 ug/ mL) were added and incubated for 4 days. The cell suspensions were sub-cultured with fresh medium containing 1000 U/mL rhIL-2. The cells were washed, and fresh medium was replaced every 3 days for 2 weeks. Culture media were removed by 3 washes with normal saline. Cells were resuspended in normal saline with human serum albumin and diverted into a transfer pack.

Treatment

Each patient received a total of 0.5–1.5×108/kg CIK cells per transfusion (one transfusion per day for 2 days). After transfusion, rhIL-2 was subcutaneously administered (100 mU/day) for 10 consecutive days. If the patient agreed, the CIK cell transfusion protocol was repeated every 3 months for 1 year (four cycles).

Results

Survival
With a median follow-up of 29.5 months (range, 6 to 105 months), the 5-year disease-free survival (DFS) was improved from 45.0 ± 11.1% to 79.3 ± 9.2% in the CIK group. At a longer median follow-up of 35.5 months, the 5-year OS was estimated at 90 ± 6.7% for CIK versus 55 ± 11.1% for control.
Side Effects
No severe side effects were recorded during or after CIK cell transfusions, except in one male patient, aged 47 years, who had mild flu-like symptoms, which were naturally quickly relieved.

Conclusion

Autologous CIK cell immunotherapy has emerged as a safe and efficacious option to improve the prognosis of patients with high-risk DLBCL after the first CR.

Article Reference link: click here

Scientific article publishing date :6/22/2020

Immucura identifier BSC21_226EN

ALL SCIENTIFIC PAPERS
CONTACT US